NEW YORK – Rocket Pharmaceuticals is discussing next steps to complete a pivotal Phase II trial of its Danon disease gene therapy, RP-A501, with the US Food and Drug Administration based on promising ...
The firm also expects topline data from a trial of its gene therapy for rare eye diseases caused by mutations in the BEST1 gene in September.
The network of community oncology practices eventually hopes to integrate the tool with its genomic databases.
The firm's personalized immunotherapy DISP-10 combines an engineered tumor-specific virus with BMS's CAR T-cell therapy Abecma.
If the FDA approves lonvo-z, Intellia expects it will be able to launch the drug, its first commercial product, in the first ...
The firm's approved product Avmapki Fakzynja Co-Pack also returned to sequential growth in Q2 helped by a refocused commercial strategy.
NEW YORK – Hangzhou, China-based CellOrigin has enlisted Walvax Biotechnology to help launch an investigator-initiated trial testing an in vivo GPC3-targeted CAR therapy in patients with ...
NEW YORK – IQVIA will support Boston-based biopharma Medera Therapeutics' clinical trials of gene therapies for cardiovascular diseases, the companies announced Tuesday. Durham, North Carolina-based ...
The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results